Last reviewed · How we verify

Heavy Bupivacaine

Diskapi Yildirim Beyazit Education and Research Hospital · FDA-approved active Small molecule

Heavy bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Heavy bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Spinal anesthesia for surgical procedures, Local infiltration anesthesia.

At a glance

Generic nameHeavy Bupivacaine
Also known asmarcaine heavy
SponsorDiskapi Yildirim Beyazit Education and Research Hospital
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby preventing depolarization and nerve impulse transmission. The 'heavy' formulation refers to bupivacaine combined with dextrose (hyperbaric solution), which increases density and allows for controlled spinal distribution during intrathecal administration. This formulation is used primarily for spinal anesthesia in surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: